RxDoctor Payments Data

Sandrine Martin

Physician Assistant · Cherry Hill, NJNPI 1225283476

Payments from drug & device makers

$1,057in general payments, 2019–2025

Across 42 payments — averaging $25.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$264
  • AbbVie$248
  • Biohaven Pharmaceutical Holding Company Ltd.$133
  • SK Life Science, Inc.$118
  • Impel Pharmaceuticals Inc.$105
  • Amgen$64
  • plus $125 from 7 others

What the payments were for

  • Food & beverage$1,057100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,057 in reported general payments places this provider in the 75th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$95,902
Medicare patients
88
Services billed
12,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant44$56,953
KeppraLevetiracetam16$32,121
Nurtec OdtRimegepant Sulfate29$31,793
BriviactBrivaracetam17$29,078
Aimovig AutoinjectorErenumab-Aooe33$27,416
Ajovy AutoinjectorFremanezumab-Vfrm16$19,266
LamictalLamotrigine18$17,777
ValtocoDiazepam19$13,936
Emgality PenGalcanezumab-Gnlm14$10,124
Oxcarbazepine70$8,919
Memantine Hcl ErMemantine Hcl33$5,052
Topiramate96$3,999
Sumatriptan Succinate37$3,770
Levetiracetam135$3,735
Frovatriptan Succinate14$2,512

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$248$56,95344 claims
UCB, Inc.Briviact$17$29,07817 claims
Neurelis, Inc.Valtoco$28$13,93619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →